期刊文献+

他汀类药肾保护作用的研究进展 被引量:5

暂未订购
导出
摘要 他汀类药(羟甲戊二酰辅酶A还原酶抑制剂)通过竞争性抑制内源性胆固醇合成限速酶(HMG-CoA)还原酶,阻断细胞内羟甲戊酸代谢途径,抑制细胞内胆固醇合成.目前常用的他汀类药如表1所示.临床研究证实,他汀类药可降低动脉粥样硬化相关事件的发病率和病死率,因此是有效调节血脂代谢异常与预防临床事件的经典药物.有临床观察提示,他汀类药通过纠正血脂代谢紊乱,可降低肾脏疾病患者发生缺血性心血管疾病如冠心病和缺血性脑卒中等危险;此外他汀类药的不依赖降脂作用的多效性也参与肾脏保护,如保护受损内皮、抗炎、抗氧化、抗纤维化等作用.但是,也有病例报道他汀类药对肾脏可能有损害作用.因此,认识他汀类药对肾脏功能的获益及风险非常重要.本文将针对他汀类药对心血管疾病(CVD)人群及慢性肾脏病(CKD)人群肾脏保护作用的最新进展进行综述.
出处 《中国医院用药评价与分析》 2014年第2期113-115,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
  • 相关文献

参考文献28

  • 1Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction; the atherosclerosis risk in communities study [J]. Kidney Int, 2000,58 ( 1 ) ; 293-301.
  • 2Samuels son 0, Attman PO, Knight -Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency [J] . J Am Soc Nephrol , 1998 ,9 (8) ; 1482-1488.
  • 3Samuelsson 0, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency [J]. Nephrol Dial Transplant, 1997 ,12 (9) ; 1908-1915.
  • 4Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study [J]. Diabetes Care, 2003,26 (5) ; 1402- 1407.
  • 5Coonrod BA, Ellis D, Becker DJ, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study [J]. Diabetes Care ,1993 ,16( 10); 1376-1383.
  • 6Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias; the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society ( EAS) [J]. Atherosclerosis, 2011 , 217(Suppll) ;SI44.
  • 7Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease [J]. J Am Soc Nephrol, 2005, 16 ( 12) ; 3748- 3754.
  • 8Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors ( statins ) for people with chronic kidney disease not requiring dialysis [J]. Cochrane Database Syst Rev ,2009 (2) : CD007784.
  • 9Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study [J].] Am Coli Cardiol, 2008, 51 (15) :1448-1454.
  • 10Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [J].N Engl] Med,2005,353(3) :238-248.

同被引文献48

引证文献5

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部